| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2023―Nov―22 |
The natural virome and pandemic potential: Disease X |
Philip Lawrence, Michelle Heung, Julia Nave, Christoph Henkel, Beatriz Escudero-Pérez |
| 2 |
[GO] |
2023―Oct―10 |
Pathogenesis of severe acute respiratory syndrome coronavirus-2 in nonhuman primates |
Taylor Saturday, Neeltje van Doremalen |
| 3 |
[GO] |
2023―Oct―02 |
Transmission of severe acute respiratory syndrome coronavirus 2 from humans to animals: is there a risk of novel reservoirs? |
Leira Fernández-Bastit, Júlia Vergara-Alert, Joaquim Segalés |
| 4 |
[GO] |
2023―Aug―28 |
Antigenic evolution of SARS coronavirus 2 |
Anna Z Mykytyn, Ron AM Fouchier, Bart L Haagmans |
| 5 |
[GO] |
2023―Aug―19 |
Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine |
Jason Yeung, Tian Wang, Pei-Yong Shi |
| 6 |
[GO] |
2023―Jun―07 |
Broadly neutralizing antibodies against COVID-19 |
Daming Zhou, Jingshan Ren, Elizabeth E Fry, David I Stuart |
| 7 |
[GO] |
2023―May―11 |
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19 |
Sam Afkhami, Alisha Kang, Vidthiya Jeyanathan, Zhou Xing, Mangalakumari Jeyanathan |
| 8 |
[GO] |
2023―Jan―18 |
The role of influenza A virus and coronavirus viral glycoprotein cleavage in host adaptation |
Miriam Ruth Heindl, Eva Böttcher-Friebertshäuser |
| 9 |
[GO] |
2021―Dec―30 |
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses |
Rong Xiang, Yang Wang, Lili Wang, Xiaoqian Deng, Shanshan Huo, Shibo Jiang, Fei Yu |
| 10 |
[GO] |
2021―Dec―11 |
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines |
Adam N Pelletier, Rafick P Sekaly, Jeffrey A Tomalka |
| 11 |
[GO] |
2021―Dec―11 |
Immune responses to human respiratory coronaviruses infection in mouse models |
Zhen Zhuang, Donglan Liu, Jing Sun, Fang Li, Jincun Zhao |
| 12 |
[GO] |
2021―Dec―04 |
A structural view of the SARS-CoV-2 virus and its assembly |
Nathan Hardenbrook, Peijun Zhang |
| 13 |
[GO] |
2021―Nov―24 |
Editorial overview: Viral immunology before COVID-19 |
Annette Oxenius, Allan J Zajac |
| 14 |
[GO] |
2021―Nov―11 |
Host cell-intrinsic innate immune recognition of SARS-CoV-2 |
Emily A Madden, Michael S Diamond |
| 15 |
[GO] |
2021―Nov―09 |
Phage therapy for secondary bacterial infections with COVID-19 |
Nannan Wu, Li-Kuang Chen, Tongyu Zhu |
| 16 |
[GO] |
2021―Sep―08 |
Structure of SARS-CoV-2 Spike Protein |
Jun Zhang, Tianshu Xiao, Yongfei Cai, Bing Chen |
| 17 |
[GO] |
2021―Aug―21 |
Know your enemy and know yourself - the case of SARS-CoV-2 host factors |
Wai Suet Lee, Meisam Yousefi, Biao Guo Yan, Cythia Lingli Yong, Yaw Shin Ooi |
| 18 |
[GO] |
2021―Aug―20 |
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets |
Asmaa Hachim, Niloufar Kavian, Sophie A Valkenburg |
| 19 |
[GO] |
2021―Aug―17 |
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19? |
Ivan Zanoni |
| 20 |
[GO] |
2021―Jul―24 |
Proteases and variants: context matters for SARS-CoV-2 entry assays |
Christian S Stevens, Kasopefoluwa Y Oguntuyo, Lee Benhur |
| 21 |
[GO] |
2021―Jul―13 |
COVID-19, the first pandemic in the post-genomic era |
Lucy van Dorp, Charlotte J Houldcroft, Damien Richard, François Balloux |
| 22 |
[GO] |
2021―Jun―29 |
Time to “Mind the Gap” in Novel Small Molecule Drug Discovery for Direct-Acting Antivirals for SARS-CoV-2 |
Colleen B Jonsson, Jennifer E Golden, Bernd Meibohm |
| 23 |
[GO] |
2021―Jun―29 |
Animal models of SARS-CoV-2 transmission |
Rory D de Vries, Barry Rockx, Bart L Haagmans, Sander Herfst, Marion PG Koopmans, Rik L de Swart |
| 24 |
[GO] |
2021―Jun―19 |
Natural killer cells and unconventional T cells in COVID-19 |
Niklas K Björkström, Andrea Ponzetta |
| 25 |
[GO] |
2021―Jun―19 |
Progress and pitfalls of a year of drug repurposing screens against COVID-19 |
Julien Sourimant, Megha Aggarwal, Richard K Plemper |
| 26 |
[GO] |
2021―Jun―18 |
Developing A Direct Acting, Orally Available Antiviral Agent in a Pandemic: The Evolution of Molnupiravir as a Potential Treatment for COVID-19 |
George R Painter, Michael G Natchus, Oren Cohen, Wendy Holman, Wendy P Painter |
| 27 |
[GO] |
2021―Jun―03 |
The impact of high-resolution structural data on stemming the COVID-19 pandemic |
Robert M Cox, Richard K Plemper |
| 28 |
[GO] |
2021―May―12 |
Remdesivir for the Treatment of Covid-19: The Value of Biochemical Studies |
Götte Matthias |
| 29 |
[GO] |
2021―May―04 |
SARS-CoV-2 vaccines - The biggest medical research project of the 21st century |
Drishya Kurup, Matthias J Schnell |
| 30 |
[GO] |
2021―Apr―27 |
Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection |
Koen Vandyck, Jerome Deval |
| 31 |
[GO] |
2021―Apr―21 |
Microbiota as a potentially-modifiable factor influencing COVID-19 |
Vu L Ngo, Andrew T Gewirtz |
| 32 |
[GO] |
2021―Apr―06 |
Structure and function of SARS-CoV-2 polymerase |
Hauke S Hillen |
| 33 |
[GO] |
2021―Apr―06 |
Animal Models for SARS-CoV-2 |
Chung-Young Lee, Anice C Lowen |
| 34 |
[GO] |
2021―Mar―10 |
Coronavirus entry: how we arrived at SARS-CoV-2 |
Gary R Whittaker, Susan Daniel, Jean K Millet |
| 35 |
[GO] |
2020―Sep―10 |
Editorial overview: Combating measles during a COVID-19 pandemic |
Rik L de Swart, Makoto Takeda |
| 36 |
[GO] |
2020―Jun―04 |
The continued epidemic threat of SARS-CoV-2 and implications for the future of global public health |
Timothy P Sheahan, Matthew B Frieman |
